Saratoga Investment Corp. NT 23 SAB
Set alert
As of Jan 8, 10:03 AM ET
- Open
- 25.63
- Prev close
- 25.62
- Mkt cap
- 150.76M
- Vol
- 3.00K
- Avg vol
- 69.92K
- EPS
- 2.94
- P/E
- 8.73
- Div yield
- 0.00%
More statistics
- Low
- 25.62
- High
- 25.74
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 189,334.28
- 200-d avg
- 188,533.58
News
3 days ago globenewswire.com
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Presentation will highlight Virtue SAB's fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.…
3 days ago globenewswire.com
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
1 week ago marketbeat.com
SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
Executives from Healios and SAB Biotherapeutics NASDAQ: SABS outlined their approaches to developing scalable biologic therapies during a Chardan discussion focused on complex treatments designed for…
1 week ago globenewswire.com
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to…
2 weeks ago globenewswire.com
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
2 weeks ago globenewswire.com
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes
1 month ago globenewswire.com
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
1 month ago globenewswire.com
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
2 months ago globenewswire.com
SAB BIO to Participate in Upcoming Investor Conferences
MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
2 months ago marketbeat.com
SAB Biotherapeutics Q2 Earnings Call Highlights
SAB Biotherapeutics NASDAQ: SABS said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter…
2 months ago globenewswire.com
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected…
3 months ago globenewswire.com
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage…
4 months ago globenewswire.com
4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board
CAMBRIDGE, UK – June 15, 2026 – 4basebio PLC (AIM: 4BB), a specialist in specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, today announces the…
5 months ago globenewswire.com
SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D Data will highlight deeper mechanistic…
5 months ago marketbeat.com
SAB Biotherapeutics Q1 Earnings Call Highlights
SAB Biotherapeutics NASDAQ: SABS said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a…
5 months ago globenewswire.com
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027
6 months ago globenewswire.com
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
6 months ago globenewswire.com
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support…
6 months ago globenewswire.com
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving…
6 months ago seekingalpha.com
SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes
SAB Biotherapeutics is a clinical-stage biotech centered on SAB-142, a disease-modifying T1D candidate targeting both stage 2 and stage 3 patients. SAB-142 may preserve beta-cell function and…
-
12 years ago benzinga.com
Bloomberg: Will Anheuser-Busch Explore M&A Opportunity Outside Of Alcohol?
Bloomberg: Will Anheuser-Busch Explore M&A Opportunity Outside Of Alcohol?